30 completed, 11 terminated, 4 unknown, 3 active not recruiting. 57 Phase 2, 10 Phase 1, 2 Phase 3.
Follow Adrucil: new trials by email Literature Review of Adrucil trials Research Report on Adrucil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-08-31 | 2026-06-23 |
| 5-Fluorouracil Response and Optimization STudy (The FROST Trial) 5-Fluorouracil - Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma | Phase 2 | Recruiting | Washington University School of Medicine | 46 | 2026-04-21 | 2026-04-27 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 96 | 2024-04-01 | 2024-03-15 |
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Terminated | Kimberly Perez, MD | 8 | 2023-01-06 | 2024-12-17 |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil - Endometrial Cancer, Gastric Cancer | Phase 2 | Recruiting | AstraZeneca | 454 | 2022-09-06 | 2026-09-23 |
| NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer Durvalumab, Oxaliplatin, Irinotecan - Pancreatic Cancer | Phase 2 | Active not recruiting | Australasian Gastro-Intestinal Trials Group | 20 | 2022-05-20 | 2026-05-06 |
| Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA - Malignant Tumor of Pancreas Metastatic to Liver | Phase 2 / Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2021-11-01 | 2022-04-01 | |
| FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer Digoxin, 5Fluorouracil, Calcium Leucovorin - Pancreas Cancer, Adenocarcinoma of the Pancreas | Phase 2 | Terminated | University of Nebraska | 11 | 2021-02-12 | 2026-10-21 |
| Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Nivolumab, relatlimab, Oxaliplatin - Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction | Phase 2 | Unknown | University Hospital, Essen | 21 | 2019-09-26 | 2024-03-12 |
| FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Fluorouracil, Irinotecan Hydrochloride, leucovorin calcium - Biliary Tract Cancer | Phase 2 | Withdrawn | Samsung Medical Center | 2019-09-06 | 2022-06-15 | |
| Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Oxaliplatin, Leucovorin, Irinotecan Hydrochloride - Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 45 | 2019-06-12 | 2026-01-13 |
| FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D - Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer | Phase 2 | Completed | Al B. Benson, III, MD | 39 | 2017-09-21 | 2024-02-06 |
| Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer nab-paclitaxel, Carboplatin, Nivolumab - HPV-Related Squamous Cell Carcinoma, HNSCC | Phase 2 | Completed | University of Chicago | 72 | 2017-06-27 | 2025-05-06 |
| FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2016-02-16 | 2018-08-16 |
| BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer Aldesleukin, Antibody Therapy, Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 2 | 2015-12-01 | 2023-05-15 |
| Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer Modufolin (arfolitixorin), Fluorouracil, Oxaliplatin - Colorectal Neoplasm | Phase 1 / Phase 2 | Completed | Isofol Medical AB | 105 | 2014-09-01 | 2020-09-09 |
| Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer 5-Fluorouracil, Leucovorin, Irinotecan - Colon Cancer | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 100 | 2014-05-06 | 2025-05-18 |
| Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Sym004 (12 mg/kg), Sym004 (9/6 mg/kg), Best Supportive Care (BSC) - Metastatic Colorectal Cancer | Phase 2 | Completed | Symphogen A/S | 254 | 2014-03-06 | 2019-04-16 |
| S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer PEGPH20, Oxaliplatin, Leucovorin - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | SWOG Cancer Research Network | 126 | 2014-01-23 | 2024-02-09 |
Showing 20 of 57. Sign in to see all of them.
Pancreatic Neoplasms (11) · Colorectal Neoplasms (8) · Stomach Neoplasms (7) · Esophageal Neoplasms (6) · Colonic Neoplasms (5) · Breast Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Rectal Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Anal Canal Carcinoma (2) · Anus Neoplasms (2) · Biliary Tract Neoplasms (2) · Carcinoma, Squamous Cell (2) · Gastrointestinal Diseases (2) · Head and Neck Neoplasms (2)
M.D. Anderson Cancer Center (16) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · ECOG-ACRIN Cancer Research Group (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Roswell Park Cancer Institute (2) · UNC Lineberger Comprehensive Cancer Center (2) · University of California, San Francisco (2) · Washington University School of Medicine (2) · AIDS Malignancy Consortium (1) · Al B. Benson, III, MD (1) · AstraZeneca (1) · Australasian Gastro-Intestinal Trials Group (1) · Barbara Ann Karmanos Cancer Institute (1) · Eastern Cooperative Oncology Group (1)
United States (48) · Italy (5) · Germany (4) · France (3) · Spain (3) · Australia (2) · Belgium (2) · Canada (2) · Poland (2) · South Korea (2) · United Kingdom (2) · Austria (1) · China (1) · Denmark (1) · Greece (1)
Jaffer Ajani, MD (3) · Joseph A. Sparano, MD (2) · Lisa Licitra, MD (2) · Marco Benazzo, MD (2) · Piero Nicolai, MD (2) · Vincent Chung (2) · Al B. Benson, MD (1) · Andrea Sponghini, MD (1) · Anthony Shields (1) · Arlene Siefker-Radtke, MD (1) · Ashwin Somasundaram, MD (1) · Boston Biomedical (1) · Christine Auberle, MD (1) · Daniel T Chang (1)
PMID 23293700, PMID 23975663, PMID 24669015, PMID 26908161, PMID 27937092, PMID 27978579, PMID 29218623, PMID 29235564, PMID 29506988, PMID 29879283, PMID 30817250, PMID 32939319, PMID 33099678, PMID 36183444, PMID 38842838, PMID 40340830
P30CA016672 (3), U10CA023318 (2), U10CA180888 (2), 2014 (1), 2023 (1), K23CA121994 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA016056 (1), P30CA022453 (1), P50CA091846 (1), P50CA127297 (1), R01CA093871 (1), R33CA127055 (1)